Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FDA Expands Approval Of Breast Cancer Drug Kisqali
Novartis CEO says FDA's extended approval of breast cancer drug is a 'landmark' for the firm
Vas Narasimhan, CEO of Novartis, comments on the progress of the firm's Kisqali metastatic breast cancer drug after the company recently received an extended approval for it from the U.S. Food and Drug Administration.
FDA expands approval of breast cancer drug Kisqali to earlier-stage patients
The FDA expanded the approval of Kisqali, a drug for metastatic breast cancer, to treat patients with earlier stage cancer, Novartis said.
Breast cancer drug Kisqali gets FDA approval to prevent cancer recurrence
The breast cancer drug Kisqali has received FDA approval to reduce cases of cancer recurrence. The drug was found to reduce the chances of a patient's breast cancer coming back by 25%.
FDA OKs Adjuvant Ribociclib in Earlier Stage Breast Cancer
Unlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be lymph-node positive to receive ribociclib after surgery.
FDA expands approval for drug to treat early-stage breast cancer
The Food and Drug Administration expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease. NBC News' Kathy Park speaks to a woman who took the drug while it was in clinical trials and is now cancer free.
FDA expands use of Kisqali to early stage breast cancer patients
Women with early stage breast cancer may now take Kisqali, a medication already approved for advanced disease.
Novartis Breast Cancer Drug Found To Cut Disease Recurrence
Novartis said its Kisqali breast cancer drug produced longer success for those with certain forms of the disease.
Kisqali wins FDA nod for breast cancer treatment: Dosage, effectiveness and side effects of the breakthrough drug
The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It targets high-risk HR-posit
FDA awards Novartis expanded approval for breast cancer therapy
The potential market for the Novartis drug Kisqali could grow markedly, now that certain early-stage breast cancer patients will be able to receive it.
FDA Approves Adjuvant Ribociclib Plus AI Therapy for HR+, HER2- Breast Cancer
The Food and Drug Administration approved ribociclib plus an aromatase inhibitor for hormone receptor (HR)–positive, HER2-negative stage II and III early breast cancer that has a high risk of recurrence.
FDA expanded their approval on drug cancer drug
First News
2h
on MSN
FDA’s new mandate shifts what patients should know about breast density
Mammogram providers are now federally required to tell their patients about their breast density. The new U.S. Food and Drug ...
19h
on MSN
Study confirms fibrosis as a prognostic indicator in the most common breast cancer
The most common breast cancer is HER2-negative, so called because it has low amounts of one of the proteins that contribute ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Kentucky judge fatally shot
Secret Service probing post
FCC chair denies Trump call
Boy kills bear, saves father
Ban called for in TX schools
Cancels appearance w/ Duda
Families lose appeal
Body found in SUV
To get a second moon
NYC subway joyride arrest
Man charged for threats
Hold campaign event in MI
MS sheriff's office probe
Stein's ballot bid rejected
Vows to remain in race
Collapse hazard recall
Recalling 449K+ vehicles
Raises settlement offer
'Targeted strike' in Beirut
PGA welcomes LIV players
Gun case sentencing delay
$3B for battery projects
Retires after 17 seasons
FTC on privacy controls
To visit US next week
Brazil threatens daily fines
160M euros to Ukraine
COVID, Wuhan market link
Overdose deaths drop in US
Makes MLB history
Feedback